Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and
efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of
protein in their urine at the time of screening.